Table 4 Studies reporting at least one positive outcome and ≥ 50% significant outcomes in favour of CDSS
| Â | Before Drug Selection (n = 26) n/N (%) | After Drug Selection (n = 12) n/N (%) | Monitoring (n = 23) n/N (%) | |||
|---|---|---|---|---|---|---|
|  | At least one positive outcome | ≥ 50% statistically significant outcomes | At least one positive outcome | ≥ 50% statistically significant outcomes | At least one positive outcome | ≥ 50% statistically significant outcomes |
Overall | 24/26 (92) | 12/26 (46) | 12/12 (100) | 7/12 (58) | 18/23 (78) | 8/23 (35) |
Initiation of CDSS | Â | Â | Â | Â | Â | Â |
System | 19/20 (95) | 12/20 (60) | 12/12 (100) | 7/12 (58) | 9/11 (82) | 6/11 (55) |
User | 2/3 (67) | 0/3 (0) | NA | NA | 9/11 (82) | 2/11 (18) |
Mixed/Unclear | 3/3 (100) | 0/3 (0) | NA | NA | 0/1 (0) | 0/1 (0) |
Clinical Setting | Â | Â | Â | Â | Â | Â |
Institutional | 5/5 (100) | 3/5 (60) | 5/5 (100) | 4/5 (80) | 6/7(86) | 3/7 (43) |
Ambulatory Care | 18/20 (90) | 8/20 (40) | 7/7 (100) | 3/7 (43) | 10/14 (71) | 4/14 (29) |
Both | 1/1 (100) | 1/1 (100) | NA | NA | 2/2 (100) | 1/2 (50) |
Mode of Delivery | Â | Â | Â | Â | Â | Â |
Multi-faceted | 13/15 (87) | 5/15 (33) | NA | NA | 5/7 (71) | 2/7 (29) |
CDSS only | 11/11(100) | 7/11 (64) | 12/12 (100) | 7/12 (58) | 13/16 (81) | 6/16 (38) |
Clinical Area | Â | Â | Â | Â | Â | Â |
Cardiovascular | 13/16 (81) | 4/16 (25) | 1/1 (100) | 0/1 (0) | 2/3 (67) | 1/3 (33) |
Antibiotics | 2/2 (100) | 1/2 (50) | 6/6 (100) | 4/6 (67) | 1/1 (100) | 0/1 (0) |
Vaccinations | 8/9 (89) | 5/9 (56) | NA | NA | NA | NA |
Respiratory | 1/2 (50) | 0/2 (0) | 3/3 (100) | 1/3 (33) | 2/5 (40) | 1/5 (20) |
Anticoagulants | 3/3 (100) | 2/3 (67) | NA | NA | 9/9 (100) | 2/9 (22) |
Elderly | NA | NA | 4/4 (100) | 2/4 (50) | 0/1 (0) | 0/1 (0) |
Osteoporosis | 2/2 (100) | 1/2 (50) | NA | NA | NA | NA |
Other | 3/4 (75)a | 3/4 (75)a | 2/2 (100)b | 2/2 (100)b | 5/6 (83)c | 4/6 (67)c |